Treatment for PMDD
First-line treatment for PMDD is continuous or luteal-phase SSRIs (sertraline 50-150 mg/day, fluoxetine 10-20 mg/day, escitalopram 10-20 mg/day, or paroxetine 12.5-25 mg/day), with continuous paroxetine showing the greatest effect across all symptom domains. 1, 2, 3
Pharmacologic Treatment Algorithm
First-Line: SSRIs
- Continuous dosing is most effective, though luteal-phase-only dosing (14 days before menses) is also efficacious 1, 2
- Specific agents and doses:
- Sertraline 50-150 mg daily
- Fluoxetine 10-20 mg daily
- Escitalopram 10-20 mg daily
- Paroxetine 12.5-25 mg daily
- Network meta-analysis demonstrates continuous paroxetine has superior efficacy across emotional, physical, and behavioral symptom domains 1
- SSRIs work rapidly in PMDD (within days), unlike their delayed effect in major depression 2, 3
Second-Line: Combined Oral Contraceptives
- Drospirenone/ethinyl estradiol 24/4 regimen (3 mg drospirenone + 20 mcg ethinyl estradiol for 24 days, 4 inactive days) is the most effective COC formulation 1, 2
- Particularly effective for both physical and emotional symptoms 1
- Consider as first-line if contraception is desired or if patient prefers hormonal approach 3
Third-Line Options
- GnRH agonists with add-back hormone therapy for severe, refractory cases 4, 3
- Cognitive Behavioral Therapy (CBT): Reduces functional impairment, depressed mood, anxiety, mood swings, irritability, insomnia, and conflict 2, 3
- Can be used as monotherapy or combined with pharmacotherapy
- Particularly effective for: functional impairment, feelings of hopelessness, sensitivity to rejection, and symptom-related disability 2
Treatment Selection Criteria
Choose SSRIs when:
- Predominant mood symptoms (irritability, anger, mood swings, depression)
- No contraceptive needs
- Rapid symptom relief desired
- Previous positive response to antidepressants
Choose drospirenone/EE 24/4 when:
- Contraception desired
- Prominent physical symptoms (bloating, breast tenderness)
- Patient preference for hormonal management
- SSRIs contraindicated or not tolerated
Add or switch to CBT when:
- Functional impairment is primary concern
- Patient prefers non-pharmacologic approach
- Inadequate response to medication alone
- Interpersonal conflict is prominent 2, 3
Diagnostic Confirmation Required
Before initiating treatment, confirm diagnosis with prospective daily symptom tracking for at least 2 consecutive menstrual cycles using validated tools (DRSP - Daily Record of Severity of Problems, or PRISM - Prospective Record of the Impact and Severity of Menstrual Symptoms) 3, 5, 6
Key diagnostic features to document:
- Symptoms present in luteal phase (last 2 weeks before menses)
- Symptoms resolve within days after menstruation onset
- Symptom-free interval in follicular phase (first 2 weeks after menses)
- At least 5 symptoms total, with ≥1 core mood symptom (irritability, mood swings, anger, depression, anxiety) 3, 5
- Significant functional impairment in work, relationships, or daily activities 6
Critical Pitfalls to Avoid
- Do not diagnose PMDD based on retrospective recall alone - prospective tracking is essential as retrospective reports overestimate symptom severity 6
- Do not use standard oral contraceptives - only the 24/4 drospirenone formulation has proven efficacy; traditional 21/7 regimens are ineffective 1
- Do not confuse with premenstrual exacerbation (PME) - PME is worsening of an underlying psychiatric condition during the luteal phase, requiring treatment of the primary disorder 6
- Do not delay SSRI treatment - unlike major depression, SSRIs work within days in PMDD; if no response after 2 cycles, switch agents 2, 3
Severe Refractory Cases
For patients failing multiple medication trials with severe impairment:
- GnRH agonists (leuprolide) with estrogen/progestin add-back therapy 4, 3
- Surgical menopause (bilateral oophorectomy) is definitive but reserved for extreme cases with documented response to GnRH agonist trial 4, 3
Multimodal Approach
Combine treatments for optimal outcomes: